Thigh Infection Models for Preclinical Research

The murine thigh infection model is a gold standard in preclinical antimicrobial research. It provides a robust and reproducible system to study bacterial and fungal infections in muscle tissue, making it particularly valuable for efficacy studies. This model has been extensively used for antibiotic development and is widely accepted by regulatory agencies as a translational tool to support dose selection and clinical trial design.

At Vibiosphen, we provide validated thigh infection models in rodents that allow pharmaceutical and biotechnology companies to evaluate novel antimicrobials and antifungals under clinically relevant conditions.

 

Background of Thigh Infections

The thigh infection model is an established localized soft tissue infection model where pathogens are inoculated directly into the thigh muscle. It allows precise control of bacterial or fungal burden, reproducible readouts, and straightforward correlations with systemic drug exposure. Its clinical relevance is reinforced by:

•  The global burden of resistant Gram-positive and Gram-negative pathogens
• The use of this model in PK/PD 
• Its role in regulatory submissions for antimicrobial development
• Its adaptability for both immunocompetent and neutropenic animals, depending on study objectives
   

Rodent Models of Thigh Infections

Mouse lineages

• The primary mouse lineages used in preclinical studies are inbred strains known for their genetic uniformity, which minimizes experimental variability.
  • C57BL/6 mice have a T-helper type 1 (Th1) biased immune response, which is a cellular immune response important for fighting intracellular pathogens.
  • BALB/c mice have a T-helper type 2 (Th2) biased immune response. A Th2 response is a humoral immune response that relies on antibodies and is essential for combatting extracellular parasites.

• Outbred mice, unlike their inbred counterparts, are maintained in large, randomly bred colonies to maximize genetic variation. This heterogeneity makes each mouse genetically unique.
  • Swiss mice, OF1 and CD1

The decision to use an inbred or outbred strain depends on the specific research question. Inbred mice are for when you want to minimize all genetic variables and pinpoint the effect of a single factor. Outbred mice are for when you want to see how a factor affects a genetically varied population.

Rat lineages

• Inbred strain, meaning they are genetically uniform, and provide a consistent baseline for preclinical studies, which is essential for reproducibility.
  • Fischer 344 (F344) rats

• Outbred rats. They have a wide range of genetic variability, which better represents the genetic diversity found in the human population 
  • Sprague Dawley rats 
  • Wistar rats 

The decision to use an inbred or outbred strain depends on the specific research question. Inbred rats are for when you want to minimize all genetic variables and pinpoint the effect of a single factor. Outbred rats are for when you want to see how a factor affects a genetically varied population.

Routes of Administration

Compounds under evaluation can be administered through several routes to reflect clinical usage and pharmacological profiles:

• Oral gavage 
• Intraperitoneal route
• Intravenous route
• Subcutaneous route
• Intramuscular route
• Intranasal route
• Inhalation / aerosolization route

• Intratracheal route

   

This versatility allows us to design tailored studies that align both the infection route and the therapeutic administration route with the intended clinical application.

Pathogens Studied in Vibiosphen Thigh Models

Vibiosphen has access to validated bacterial and fungal strains, and can also adapt models to client-specific isolates.

Bacterial thigh infections

• Staphylococcus aureus (including MRSA)
• Enterococcus faecium (including VRE)
• Escherichia coli
• Klebsiella pneumoniae
• Pseudomonas aeruginosa
• Acinetobacter baumannii
• And further strains available (please ask for specific pathogens including BSL3)
   

These models are especially valuable for evaluating new antibiotics and tackling the global issue of antimicrobial resistance.

Fungal thigh infections

• Candida albicans
• Candida auris
• Candida tropicalis
• And further strains available (please ask for specific pathogens)
   

These models are particularly useful for evaluating novel antimicrobials, antifungals, and adjunctive immunotherapies in the context of thigh infection.

Readouts in Thigh Infection Models

To ensure robust and translational outcomes, Vibiosphen applies a wide range of validated readouts:

• Microbiological burden: Quantification of CFU in infected thigh tissue
• Pharmacodynamics analysis: Correlation of drug concentration in plasma and tissue with efficacy
• Survival and clinical scoring: Comprehensive monitoring of mouse welfare and clinical signs. Evaluation of weight lossa and behavior as indicators of disease severity
• Histopathology: Evaluation of local inflammation, necrosis, and tissue damage
• Immunological endpoints: Cytokine and biomarker profiling when relevant

This model is particularly valuable for evaluating the efficacy of novel antimicrobials and antifungals in a controlled localized infection setting, providing reliable data on therapeutic potential before advancing to clinical development.
 

Applications of Vibiosphen’s Thigh Infection Models

Our thigh infection models are used in a wide range of preclinical research applications:

• Pharmacodynamics (PD) studies to establish optimal dosing 
• Comparative efficacy studies of new antimicrobials versus standards of care
• Evaluation of antifungal efficacy in localized muscle infections
• Screening and optimization of novel therapeutic candidates
• Translational data generation 
   

Why Choose Vibiosphen?

• Proven expertise in infectious disease research
• Flexible and customized study designs adapted to sponsor requirements (see downloads available as example) 
• Advanced facilities to ensure reliable and reproducible results (BSL2 and BSL3) 
• Strong collaborations with pharmaceutical companies, biotech firms, and academic partners

Vibiosphen combines scientific excellence with industry know-how to deliver actionable preclinical data that drive innovation in infectious disease therapeutics.

Contact Us

If you are developing new treatments or vaccines against pulmonary infections, Vibiosphen can help accelerate your research.

Contact us today to discuss your project and explore how our pulmonary infection models can support your development strategy. 

We will be pleased to facilitate your project by providing a customized study design to your project objectives.